Have a Claim?

Click here for a confidential contact or call:


May 12, 2015

Posted  May 12, 2015

The FTC charged Lunada Biomedical with misleading claims about weight loss. The FTC has filed a federal court complaint seeking to prohibit the company and its principals from advertising that their dietary supplement Amberen causes substantial weight loss for women over 40, and that the weight loss is clinically proven. Between 2010 and 2013, Lunada sold almost $65 million worth of Amberen nationwide. Jessica Rich, Director of the FTC’s Bureau of Consumer Protection, said “Lunada marketed Amberen to women over 40 as ‘clinically proven’ to cause weight loss, but their own studies didn’t support those claims.”